newsfilter
← Latest News
Business Wire·

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress

- Results from the BEYOND Phase 2 trial in non-transfusion dependent beta-thalassemia to be presented during Presidential Symposium – - Additional presentations to feature data from longer-term use of REBLOZYL in populations of patients with beta-t